Antibiotic therapy in cystic fibrosis;L'antibiotherapie dans la mucoviscidose. II. Strategie antibiotique

Archives de Pediatrie

Volumn 7, Issue 6, 2000, Pages 645-656

  Sermet Gaudelus, I ^a   Ferroni, A ^b   Gaillard, J L ^c   Silly, C ^a   Chretiennot, C ^a   Lenoir, G ^a   Berche, P ^b  

^a Unité fonctionnelle de Mucoviscidose Service de Pneumo Pédiatrie HÔpital Necker Enfants Malades   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c RAYMOND POINCARÉ HOSPITAL   (France)

Author keywords

Antibiotics; Cystic fibrosis; Drug resistance, microbial

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COLONIZATION; DISEASE EXACERBATION; GRAM NEGATIVE INFECTION; INFLUENZA; LUNG FIBROSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEPHROTOXICITY; OTOTOXICITY; BACTERIAL INFECTION; CYSTIC FIBROSIS; HUMAN; LUNG DISEASE; MICROBIOLOGY; REVIEW;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CYSTIC FIBROSIS; DRUG RESISTANCE, MICROBIAL; HUMANS; LUNG DISEASES;

EID: 0034199067     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-693X(00)80134-7     Document Type: Article

References (103)

1. Ramsey BW. Drug therapy. Managment of pulmonary disease in patients with cystic fibrosis. N Engl J Med 1996 ; 335 : 179-88.
2. Foucaud P, Bingen E, Lambert-Zechovsky N, Navarro J. Infection à pyocyanique dans la mucoviscidose. Stratégies thérapeutiques. Presse Méd 1990 ; 19 : 983-5.
3. Lenoir G. Pseudomonas aeruginosa et mucoviscidose. Rev Pneumol Clin 1995 ; 51 : 151-8.
4. Burns JL, Emerson J, Stapp JR, Yim DL, Krzewinski J, Louden L, et al. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis 1998 ; 27 : 158-63.
5. Le Bourgeois M, Bingen E, Navarro J. Bases bactériologiques et traitements antibiotiques au cours de la mucoviscidose. In : G Pons, G Lenoir, J Navarro, éd. Les Médicaments de la Mucoviscidose Chez L'enfant. Paris : Springer Verlag; 1997. p. 143-53.
6. Chabanon G, Segonds C, Marty N, Dournes JL, Agueda L. Aspects microbiologiques des infections au cours de la mucoviscidose. Med Therap 1997 ; 3 : 451-7.
7. Saiman L, Edwards L. What is the association between CF pathogens and morbidity and mortality? [Abstract] In: 13th Annual North American Cystic Fibrosis Conference Seattle; 1999 Oct 7-10; Washington. Pediatr Pulmonol 1999 ; Suppl 19 : 147.
8. Wagener J, Butler S, Rabin H, Regelman W, Johnson C. New cases of Pseudomonas aeruginosa: Risk factors and outcomes. Pediatr Pulmonol 1998 ; Suppl 17 : 147-8.
9. Pier G, Grout M, Zaidi T. Cystic fibrosis tranmembrane conductance regulator is an epithelial cell receptor for clearance of Pseudomonas aeruginosa from the lung. Proc Natl Acad Sci USA 1997 ; 94 : 12088-93.
10. Hiatt PW, Grace SC, Kosinetz CA, Helioui Raboudi S, Treece DG, Taber LH, et al. Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis. PediaTrics 1999 ; 103 : 619-26.
11. Goldman MJ, Anderson GM, Stolzenberg ED, Kari VP, Zasloff M, Wilson JM, et al. Human-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 1997 ; 88 : 553-60.
12. Pasquier C, Dournes JL, Chabanon G, Marty N. The biosynthesis of Pseudomonas aeruginosa alginate regulation of a a virulence factor. Bull Inst Pasteur 1996 ; 94 : 139-49.
13. Bales R, Weiner DJ, Wilson JM. Innate immune system in CF lung disease. J Clin Invest 1999 ; 103 : 303-7.
14. Wine JJ. Genesis of cystic fibrosis lung disease. J Clin Invest 1999 ; 103 : 309-12.
15. Simmonds EJ, Conway SP, Ghoneim ATM, Ross H, Littlewood JM. Pseudomonas cepacia: A new pathogen in patients with cystic fibrosis referred to a large centre in the United Kingdom. Arch Dis Child 1990 ; 65 : 874-7.
16. Mahenthiralingam E, Bishof J, Bryne SK. Molecular speciation of Burkholderia cepacia complex strains recovered from patients with cystic fibrosis. Pediatr Pulmonol 1998 ; 17 : 307.
17. Burns JL, Krzewinski J, Nguyen CD. Molecular epidemiology of Stenotrophomonas and Alcaligenes [Abstract]. In: 13th Annual North American Cystic Fibrosis Conference Seattle; 1999 Oct 7-10; Washington. Pediatr Pulmonol 1999 ; Suppl 19 : 146.
18. Bange FC, Kirschner P, Böttger EC. Recovery of mycobacteria from patients with cystic fibrosis. J Clin Microb 1999 ; 37 : 3761-3.
19. Bellon G, Gilly R. Antibiothérapie dans la mucoviscidose: Incertitudes et réalités. Rev Mal Resp 1990 ; 7 : 203-8.
20. Mendelman PM, Smith AL, Levy J, Weber A, Ramsey B, Davis R. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am Rev Respir Dis 1985 ; 132 : 761-5.
21. Gaillard JL, Cahen P, Delacourt C, Silly C, Le Bourgeois M, Coustère C, et al. Correlation between activity of beta-lactam agents in vitro and bacteriological outcome in acute pulmonary exacerbations of cystic fibrosis. Eur J Clin Microbiol Infect Dis 1995; 14 : 291-6.
22. Perea EJ, Clavijo E, Nogales MC, Luque IG. Interaction of aminoglycosides and cephalosporins against pseudomonas aeruginosa. Correlation between interaction index and killing curve. J Antimicrob Chemother 1988 ; 22 : 175-83.
23. Marks MI. Antibiotics are not always useful in the treatment of pulmonary infections in patients with cystic fibrosis. A point of view. Pediatr Pulmonol 1996 ; 13 Suppl : 144-5.
24. Gold R, Carpentier S, Heurter H, Corey M, Levison H. Randomized trial of ceftazidime versus placebo in the management of acute respiratory exacerbations in patients with cystic fibrosis. J Pediatr 1987 ; 111 : 907-13.
25. Wolter JM, Bowler SD, McGormack JG. Are antipseudomonal antibiotics really beneficial in acute respiratory exacerbations of cystic fibrosis? Aust N Z J Med 1999 ; 29 : 15-21.
26. Smith AL, Doersbuk C, Goldmann D, Gore E, Human B, Marks M, et al. Comparison of a β-lactam alone versus β-lactam and an aminoglycosid for pulmonary exacerbations in cystic fibrosis. J Pediatr 1999 ; 134 : 413-21.
27. Denton M, Wilcox MH. Antimicrobial treatment of pulmonary colonization and infection by Pseudomonas aeruginosa in cystic fibrosis patients. J Antimicrob Chemother 1997 ; 40 : 468-74.
28. Beaudry PH, Marks MI, McDougall D, Desmond K, Rangel R. Is antipseudomonas therapy warranted in acute respiratory exacerbation in children with cystic fibrosis. J Pediatr 1980 ; 97 : 144-7.
29. Gold R, Carpentier S, Heurter H, Corey M, Levison H. Randomized trial of ceftazidime versus placebo in the managment of acute exacerbations in patients with cystic fibrosis. J Pediatr 1987 ; 111 : 907-13.
30. Rayner RJ, Hiller EJ, Ispahani P, Baker M. Haemophilus infection in cystic fibrosis. Arch Dis Child 1990 ; 65 : 255-8.
31. Bingen E. Antibiotic choice for Pseudomonas pulmonary infections in children with cystic fibrosis [Letter]. Pediatr Pulmonol 1997 ; 16 Suppl : 45.
32. Iaconis JP, Pitkin DH, Sheikkh W, Nadler H. Comparison of antibacterial activities of meropenem and six other antimicrobials against Pseudomonas aeruginosa isolates from North american studies and clinical trials. Clin Inf Dis 1997 ; 24 Suppl 2 : S191-6.
33. Levy J, Baran D, Klastersky J. Comparative study of the antibacterial activity of amikacin and tobramycin during Pseudomonas aeruginosa infection in patients with cystic fibrosis. J Antimicrob Chemother 1982 ; 10 : 227-34.
34. Conway SP, Pond MN, Watson A, Robey C, Goldman MH. Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis. Thorax 1997 ; 52 : 987-93.
35. Ghani M, Soothill BJS. Ceftazidime, gentamicin, and rifampicin, in combination, kill biofims of mucoid Pseudomonas aeruginosa. Can J Microbiol 1997 ; 43 : 999-1004.
36. Koyabashi H, Takeda H, Sakayoris S, Kawakami Y, Otsuka Y, Tamura M. Study on azithromycin in treatment of diffuse panbronchilitis. J Jpn Assoc Infect Dis 1995 ; 69 : 711-22.
37. Jaffe A, Francis J, Rosenthal M, Bush A. Long term azithromycin may improve lung function in children with cystic fibrosis. Lancet 1998 ; 4351 : 420.
38. Guillot M, Eckart P, Desrosieres H, Brouard J. Macrolides et infection à pyocyanique Ann Pédiatr [à paraître].
39. Kit AA, Sawari M, Oku D. Suppression of virulence factors of Pseudomonas aeruginosa by erithromycin. Antimicrob Chemother 1991 ; 27 : 273-84.
40. Hosoyama T, Yuge T, Takahashi S, Suzuki T, Okubo T, Iyobe S, et al. Inhibitory effect of antimicrobial agents on alginate production in Pseudomonas aeruginosa. J Antibiotics 1999 ; 52 : 65-7.
41. Tateda K, Ishii Y, Matsumoto T, Furuya N, Nagashima M, Matsunaga T, et al. Direct evidence for antipseudomonal activity of macrolides: Exposure dependent bactericidal activity and inhibition of protein synthesis by erithromycin, clarithromycin and azithromycin. Antimicrob Agent Chemother 1996 ; 40 : 2271-5.
42. Goswami SK, Kivity S, Maron Z. Erithromycin inhibits respiratory glycoconjugate secretion from human airways in vitro. Am Rev Respir Dis 1990 ; 141 : 72-8.
43. Tamaoki J, Isono K, Sakay N, Kanemura T, Konno K. Erythromycin inhibits Cl secretion across canine tracheal epithelial cells. Eur Respir J 1992 ; 5 : 234-8.
44. Altschuler EL. Azithromycin, the multidrug-resistance protein, and cystic fibrosis [Letter]. Lancet 1998 ; 351 : 1286.
45. Black PN. Antiiflammatory effects of macrolide antibiotics. Eur Respir J 1997 ; 10 : 971-2.
46. Yanagihara K, Timmo K, Sawai T, Hirakata Y, Kadota J, Koga H. Effect of clarithromycin on lymphocytes in chronic respiratory Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 1997 ; 155 : 337-42.
47. Vic P, Ategbo S, Turck D, Husson MO, Tassin E, Loeille GA, et al. Tolerance, pharmacokinetics and efficacy of once daily amikacin treatment of Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis patients. Eur J Pediatr 1996 ; 155 : 948-53.
48. Vic P, Atedbo S, Turck D, Husson MO, Launay V, Loeille GA, et al. Efficacy, tolerance and pharmacokinetics of once-daily versus thrice-daily tobramycine for Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis patients. Arch Dis Child 1998 ; 78 : 536-9.
49. Powell SH, Thompson WL, Luth MA, Luthe MA, Stern RC, Grossniklaus DA, et al. Once daily vs continuous aminoglycosid dosing : Efficacy and toxicity in animal and clinical studies of Gentamycin, Netilmycin and Tobramycin. J Inf Dis 1983 ; 147 : 918-31.
50. Guglielmo BJ, Quan LA, Stulberg MS. Pharmacokinetics of once daily versus thrice-daily tobramycin in CF patients. J Antimicrob Chemother 1996 ; 327 : 1040-2.
51. Bates RD, Nahata MC, Jones JW, McCoy K, Young G, Cox S, et al. Pharmacokinetics and safety of tobramycin after once-daily administration in patients with cystic fibrosis. Chest 1997 ; 112 : 1208-13.
52. Cappellety DM, Kang SL, Palmer SM, Rybak M. Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone or in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro model. Antimicrob Agents Chemother 1995 ; 1787-1801.
53. MacGowan AP, Bowker KE. Continuous infusion of beta-lactam antibiotics. Clin Pharmacokinet 1998 ; 35 : 391-402.
54. David TJ, Devlin J. Continuous infusion of ceftazidime in cystic fibrosis. Lancet 1989 ; i : 1454-5.
55. Kuzemko J, Crawford C. Continuous infusion of ceftazidime in cystic fibrosis [Letter]. Lancet 1989, ii : 385.
56. Vinks AATMM, Brimicombe RW, Heijerman HGM, Bakker W. Continuous infusion of ceftazidime in cystic fibrosis patients during home tratment: Clinical outcome, microbiology and pharmacokinetics. J Antimicrob Chemother; 1997 ; 40 : 125-33.
57. Byl B, Baran D, Herchuelz A, Roucloux I, Lambert C, Van der Auwera AP, et al. Sputum penetration of a single daily dose of amikacin and of continuous infusion of ceftazidime in cystic fibrosis. In: American society for microbiology, ed. Program and Abstracts of the Thirty Second Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim 1992. Abstract 209. p. 145.
58. Bergogne-Berezin E. Pharmacokinetics of antibiotics in cystic fibrosis patients with particular reference to the bronchopulmonary tree. Infection 1987 ; 15 : 288-94.
59. Touw DJ, Brimicombe RW, Hodson M, Heijerman HG, Bakker W. Inhalation of antibiotics in cystic fibrosis. Eur Respir J 1995 ; 8 : 1594-604.
60. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999 ; 340 : 23-30.
61. Lipuma JJ. Burkholderia cepacia. Management issues and new insights. Clin Chest Med 1998 ; 19 : 473-86.
62. Bonnacorsi S, Fitoussi F, Lhopital S, Bingen E. Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin and ceftazidime in combination with tobramycin, rifampin, or ciprofloxacin against Burkholderia cepacia isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 1999 ; 43 : 213-7.
63. Gilligan PH. Stenotrophomonas maltophilia, Burkholderia gladioli, and related organisms: Are they emerging pathogens in CF? In: 13th Annual North American Cystic Fibrosis Conference Seattle; 1999 Oct 7-10; Washington. Pediatr Pulmonol 1999; Suppl 19 : 117.
64. Torrens JK, Dawkins P, Conway SP, Moya E. Non tuberculosis mycobacteria in cystic fibrosis. Thorax 1998 ; 53 : 182-5.
65. Weaver LT. Prognosis in cystic fibrosis treated with continuous fluoxacillin from the neonatal period. Arch Dis Child 1979 ; 70 : 84-9.
66. Littlewood JM, Miller MG, Ghoneim AT, Ramsden CH. Nebulised colomycin for early Pseudomonas colonisation in cystic fibrosis by early treatment [Letter]. Lancet 1985 ; i : 865.
67. Valerius N, Koch C, Hoiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 1991 ; 338 : 725-6.
68. Vazquez C, Municio M, Corera M, Gaztelurrutrat L, Sojo A, Vitoria JC. Early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Acta Paediatr 1993 ; 82 : 308-9.
69. Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration in pulmonary function with cystic fibrosis. Pediatr Pulmonol 1997 ; 23 : 330-5.
70. Szaff M, Hoiby N, Flensborg EW. Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Acta Paediatr Scand 1983 ; 72 : 651-7.
71. Frederiksen B, Lanng S, Koch C, Hoiby N. Improved survival in the danish cystic fibrosis center: Results of agressive therapy. Pediatr Pulmonol 1996 ; 21 : 153-8.
72. Stutman HR. Approach to CF related pulmonary infection in the US. In: Cystic Fibrosis Pulmonary Infections. Basel: Berkahauser Verlag; 1996. p. 128-34.
73. Smith A, Redding G, Doershuk C, Goldmann D, Gore E, Hilman B, et al. Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis. J Pediatr 1988 ; 112 : 547-54.
74. Clayton RG, Diaz CE, Bashir NS, Panitch HB, Schidlow DV, Allen JL. Pulmonary function in hospitalized infants and toddlers with cystic fibrosis. J Pediatr 1998 ; 132 : 405-8.
75. Regelmann WE, Elliott GR, Warwick WJ, Clawson CC. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis 1990 ; 141 : 914-21.
76. Vic P, Ategbo S, Gottrand F, Launay V, Loeille GA, Elian JC, et al. Nutritional impact of antipseudomonas intravenous antibiotic courses in cystic fibrosis. Arch Dis Child 1997 ; 76 : 437-40.
77. Hodson ME, Penketh ARL, Batten JC. Aerosol carbenicillin and gentamycin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis. Lancet 1981 ; ii : 1137-9.
78. Jenkins SG, Kelly WC, Mason WG. Aerosolized amikacin administration to cystic fibrosis patients chronically infected with Peudomonas aeruginosa. 26th Meeting of The Cystic Fibrosis Foundation; Anaheim; California; 16-19 May 1985 [abstract].
79. Staed RJ, Hodson ME, Batten JC. Inhaled ceftazidime compared with gentamicin and carbenicillin in older patients wit cystic fibrosis. Br J Dis Chest 1987 ; 81 : 272-9.
80. Jensen T, Pedersen SS, Garne S, Heilmann C, Hoiby N, Koch C. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother 1987 ; 19 : 831-8.
81. Ramsey B, Dorkin HL, Eisenberg JED, Gibson RL, Hawood IR, Kravitz RM, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993 ; 328 : 1740-6.
82. Mukhopadhay S, Singh M, Cater JI, Ogston S, Franklin M, Olver RE, et al. Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: A meta-analysis of benefits and risk. Thorax 1996 ; 51 : 364-8.
83. Pirzada OM, Taylor CJ. Long term macrolide antibiotics improve pulmonary function in cystic fibrosis. In: 13th Annual North American Cystic Fibrosis Conference Seattle; 1999 Oct 7-10; Washington. Pediatr Pulmonol 1999; Suppl 19 : abstract 348.
84. Bosworth DG, Nielson DW. Effectiveness of home versus hospital care in the routine treatment of cystic fibrosis. Pediatr Pulmonol 1997 ; 24 : 42-7.
85. Wolter JM, Bowler SD, Nolan PJ, McCormack JG. Home intravenous therapy in cystic fibrosis: A prospective randomized trial examining clinical, quality of life and cost aspects. Eur Respir J 1997 ; 10 : 896-900.
86. Giwercman B, Meyer C, Lambert PA, Reinert C, Hoiby N. High-level beta-lactamase activity in sputum samples from cystic fibrosis patients during antipseudomonas treatment. AntiMicrob Agents Chemother 1992 ; 36 : 71-6.
87. Diver JM, Schollaardt T, Rabin HR, Thorson C, Bryan LE. Persistance mechanisms in Pseudomonas aeruginosa from cystic fibrosis patients undergoing ciprofloxacin therapy. AntimiCrob Agents Chemother 1991 ; 35 : 1538-46.
88. Smith AL, Ramsey BW, Hedges DL, Williams-Warren J, Weber A, Gore EJ, et al. Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis. Pediatr Pulmonol 1989 ; 7 : 265-71.
89. Denton M, Todd NJ, Littlewood JM. Role of antipseudomonas antibiotics in the emergence of Stenotrophomonas maltophilia in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis 1996 ; 15 : 402-5.
90. Lester LA, Oyler JL, McColley S, Cheatham J. Acquisition of Aspergillus species during treatment with aerosolized tobramycin. In: 13th Annual North American Cystic Fibrosis Conference Seattle; 1999 Oct 7-10; Washington. Pediatr Pulmonol 1999; Suppl 19 : abstract 344.
91. Kuhn RJ, Lubin AH, Jones PR, Nahata MC. Bacterial contamination of aerosol solution used to treat cystic fibrosis. Am J Hosp Pharm 1982 ; 39 : 308-9.
92. Burdge DR, Nakielna EM, Noble MA. Case control and vector studies of nosocomial acquisition of Pseudomonas cepacia in adult patients with cystic fibrosis. Infect Control Hosp Epidemiol 1993 ; 14: 127-30.
93. Pedersen SS, Jensen T, Osterhammel D, Osterhammel P. Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis. Antimicrob Agents Chemother 1987 ; 31 : 594-9.
94. Steinkamp G, Lütge M, Wurster U, Schulz-Baldes JG, Gröne HJ, Ehrich JHH. Renal function in cystic fibrosis: Proteinuria and enzymuria before and after tobramycin therapy. Eur J Pediatr 1986 ; 145n : 526-31.
95. Ring E, Eber E, Erwaz W, Zach MS. Urinary N-acetyl-β-D-glucosaminidase activity in patients with cystic fibrosis on long term gentamicin inhalation. Arch Dis Child 1998 ; 78 : 540-3.
96. Giulano RA, Verpooten GA, Verbist L. In vivo uptake kinetics of aminoglycosides in the kidney cortex of rats. J Pharmacol Exp Ther 1986 ; 236 : 470-5.
97. Sone M, Schachern PA, Paparella MM. Loss of spiral ganglion cells as primary manifestation of aminoglycoside ototoxicity. Hearing Res 1998 ; 115 : 317-23.
98. Warren RW. Rheumatologic aspects of pediatric cystic fibrosis patients treated with fluoroquinolones. Pediatr Infect Dis 1997 ; 16 : 118-22.
99. Kuhn RJ, Palmejar A, Kanga JF. Tolerability of ciprofloxacin in pediatric patients with cystic fibrosis. Adv Antimicrob AntineoPlast Chemother 1992 ; 11 : S269-71.
100. Richard D, Noursia-Arvanitakis ZS, Sollich V, Hampel BJ, Sommerauer B, Schaad UB. Oral ciprofloxacin vs intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: Comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging. Pediatr Infect Dis 1997 ; 16 : 672-8.
101. Koch C, Hjelt K, Pedersen SS, Jensen ET, Jensen T, Lanng S, et al. Retrospective clinical study of hypersensisibility reactions to aztreonam and six other beta-lactam antibiotics in cystic fibrosis patients receiving multiple treatment courses. Rev Infect Dis 1991 ; 13 Suppl 7 : S608-11.
102. Ghosal S, Taylor CJ. Intravenous desensitization to ceftazidime in cystic fibrosis patients. J Antimicrob Chemother 1997 ; 39 : 556-7.
103. Mallon P, Murphy P, Elborn S. Fever associated with intravenous antibiotics in adults with cystic fibrosis. Lancet 1997 ; 350 : 1676-7.